Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Clin Cancer Res. 2010 Jun 22;16(13):3399–3408. doi: 10.1158/1078-0432.CCR-09-3087

Figure 6.

Figure 6

CpG-ODN-treated mice develop immunity against tumor rechallenge. Normal naïve mice and CpG-ODN-treated GL261-bearing mice that had survived for at least three months after the initial tumor inoculation were rechallenged with an intracranial injection of (A) GL261 glioma (1x105) or (B) B16 F10 melanoma (1x105) cells. Tumor growth was assessed by measuring animal survival (A and B) while NK cytotoxicity assay was measured by incubating isolated brain and blood NK cells with GL261 target cells. *: p<0.05, **: p<0.001, ***: p<0.0001. n=7 mice/group for survival experiments and 4 for cytotoxicity assays. Data is representative of two separate experiments.